Abstract：Objective To investigate the effects of Dulaglutide on glycemic variability and microinflammatory state in patients with type 2 diabetes mellitus poorly controlled by Metformin. Methods A total of 118 patients with type 2 diabetes mellitus who were poorly controlled by metformin alone in Rugao People’s Hospital, Nantong University from January 2019 to January 2022 were selected as the research objects. They were divided into control group and study group by random number table method, with 59 cases in each group. The control group was treated with Metformin combined with Insulin Aspart 30, and the study group was treated with Dulaglutide on the basis of the control group. Blood glucose biochemical indexes, inflammatory indexes, islet function indexes, and drug safety were evaluated after three months of treatment in both groups. Results After treatment, the fasting blood glucose, 2-hour postprandial blood glucose, and glycosylated hemoglobin of the two groups were lower than those before treatment, and the proportion of time in range (TIR) of glucose target was higher than that before treatment, and the TIR of the study group was higher than that of the control group (P＜0.05). After treatment, the levels of interleukin-6 and high-sensitivity C-reactive protein in two groups were lower than those before treatment, and those in the study group were lower than those in the control group (P＜0.05). After treatment, homeostasis model assessment index of islet β cell (HOMA-β) in both groups were higher than those before treatment, homeostasis model assessment index of insulin resistance (HOMA-IR) were lower than those before treatment, HOMA-β in study group was higher than that in control group, HOMA-IR was lower than that in control group (P＜0.05). The incidence of nausea and vomiting in the study group was higher than that in the control group (P＜0.05). Conclusion The application of Dulaglutide in the treatment of patients with type 2 diabetes mellitus poorly controlled by Metformin can help to control blood glucose fluctuation and inhibit the expression of inflammatory factors, but it may increase nausea and vomiting.
章鸿雁1 姜冬梅2 杨婷1 蒋艺兰1▲. 度拉糖肽对二甲双胍控制不佳的2型糖尿病患者血糖波动和微炎症状态的影响[J]. 中国医药导报, 2023, 20(30): 89-92.
ZHANG Hongyan1 JIANG Dongmei2 YANG Ting1 JIANG Yilan1▲. Effects of Dulaglutide on glycemic variability and microinflammatory state in patients with type 2 diabetes mellitus poorly controlled with Metformin. 中国医药导报, 2023, 20(30): 89-92.
2023, Vol. 20 
京公网安备 11010502046598号